BRPI0411594A - derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina - Google Patents

derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina

Info

Publication number
BRPI0411594A
BRPI0411594A BRPI0411594-5A BRPI0411594A BRPI0411594A BR PI0411594 A BRPI0411594 A BR PI0411594A BR PI0411594 A BRPI0411594 A BR PI0411594A BR PI0411594 A BRPI0411594 A BR PI0411594A
Authority
BR
Brazil
Prior art keywords
alkyl
het
aryl
alkoxy
serotonin
Prior art date
Application number
BRPI0411594-5A
Other languages
English (en)
Inventor
Mark David Andrews
Alan Daniel Brown
Paul Vincent Fish
Michael Jonathan Fray
Markian Lansdell
Alan Stobie
Florian Wakenhut
Gavin Alistair Whitlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0411594A publication Critical patent/BRPI0411594A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS DE N-PIRROLIDIN-3-IL-AMIDA COMO INIBIDORES DE RE-ABSORçãO DE SEROTONINA E NORADRENALINA". Um composto da fórmula (I) e derivados farmacêutica e/ou veterinariamente aceitáveis deste, em que R¬ 1¬ é H, C~ 1~-6alquila, -C(X)Y, C~ 3-~ 8CiCloalquila, arila, het, aril-C~ 1~-4alquila, ou het-C~ 1~-4alquila, em que os grupos cicloalquila, arila ou het são opcionalmente substituídos por pelo menos um substituinte independentemente selecionado de C~ 1~-8alquila, C~ 1~-8alcoxi, OH, halo, CF~ 3~, OCF~ 3~, SCF~ 3~, hidroxi-C~ 1~-6alquila, C~ 1-~4alcoxi-C~ 1~-6alquila e C~ 1~-4alquilS-C~ 1~-4alquila; R¬ 2¬ é arila ou heteroarila, cada uma opcionalmente substituída por pelo menos um substituinte independentemente selecionado de C~ 1~8alquila, C~ 1~-8alcoxi, OH, halo, CF~ 3~, OCF~ 3~, SCF~ 3~, hidroxi-C~ 1~-6alquila, C~ 1~4alCoxi-C~ 1~-6alquila e C~ 1~-4alquil-S-C~ 1~-4alquila; R¬ 3¬ é C~ 1~-6alquila, C~ 3~-8cicloalquila, C~ 3-~8Cicloalquil-C~ 1~-6alquila, arila, het, aril-C~ 1~-4alquila ou het-C~ 1~-4alquila, em que os grupos cicloalquila, arila ou het são opcionalmente substituídos por pelo menos um substituinte independentemente selecionado de C~ 1~-6alquila, C~ 1~6alcoxi, OH, halo, CF~ 3~, OCF~ 3~, SCF~ 3~, hidroxi-C~ 1~-6alquila, C~ 1~-4alcoxi-C~ 1~-6alquila e C~ 1~-4alqUil-S-C~ 1~-4alquila; X é S ou O; Y é H, C~ 1~-6alquila, arila, het, aril-C~ 1~4alquila ou het-C~ 1~-4alquila; n é 1 ou 2, contanto que quando n for 1, m seja O ou 1 e quando n for 2, m seja 0, em que se m for 0, então * representa um centro de quiral. Os compostos da invenção exibem atividade como inibidores de re-absorção tanto de serotonina quanto de noradrenalina e portanto têm utilidade em uma variedade de áreas terapêuticas, por exemplo incontinência urinária.
BRPI0411594-5A 2003-06-17 2004-06-07 derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina BRPI0411594A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (1)

Publication Number Publication Date
BRPI0411594A true BRPI0411594A (pt) 2006-08-29

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411594-5A BRPI0411594A (pt) 2003-06-17 2004-06-07 derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina

Country Status (31)

Country Link
US (2) US7378436B2 (pt)
EP (1) EP1638933B1 (pt)
JP (1) JP4137159B2 (pt)
KR (1) KR100803796B1 (pt)
AP (1) AP2005003467A0 (pt)
AR (1) AR044715A1 (pt)
AT (1) ATE398107T1 (pt)
AU (1) AU2004247487B2 (pt)
BR (1) BRPI0411594A (pt)
CA (1) CA2530159C (pt)
CY (1) CY1110434T1 (pt)
DE (1) DE602004014372D1 (pt)
DK (1) DK1638933T3 (pt)
EA (1) EA009881B1 (pt)
EC (1) ECSP056232A (pt)
ES (1) ES2305776T3 (pt)
HR (2) HRP20050993A2 (pt)
IL (1) IL172063A0 (pt)
IS (1) IS8136A (pt)
MA (1) MA27885A1 (pt)
MX (1) MXPA05013960A (pt)
NL (1) NL1026438C2 (pt)
NZ (1) NZ544046A (pt)
PA (1) PA8605301A1 (pt)
PE (1) PE20050631A1 (pt)
PL (1) PL1638933T3 (pt)
PT (1) PT1638933E (pt)
SI (1) SI1638933T1 (pt)
TW (1) TW200505852A (pt)
UY (1) UY28360A1 (pt)
WO (1) WO2004110995A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133203T3 (de) * 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
BRPI0411594A (pt) * 2003-06-17 2006-08-29 Pfizer derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina
ES2336130T3 (es) 2004-10-18 2010-04-08 Eli Lilly And Company Derivados 1-(hetero)aril-3-amino-pirrolidina para uso como antagonistas del receptor de mglur3.
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
CA2590226A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
WO2006064336A2 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI410406B (zh) * 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
BRPI0611138A2 (pt) * 2005-06-02 2010-08-17 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst subtipo 5 e utilização dos compostos
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
US20100056497A1 (en) * 2007-01-31 2010-03-04 Dainippon Sumitomo Pharma Co., Ltd Amide derivative
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
CA2708866A1 (en) * 2007-12-19 2009-06-25 Hiroyuki Nakahira Bicyclic heterocyclic derivative
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
SI2358676T1 (sl) * 2008-11-14 2013-01-31 Theravance, Inc. Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
EP2419405A1 (en) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
AU2010273645B2 (en) 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (pt)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2238081A1 (en) 1995-11-22 1997-05-29 S. Jane Desolms Inhibitors of farnesyl-protein transferase
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
AU2001287898A1 (en) 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
HUP0303360A2 (hu) 2000-09-25 2004-01-28 Actelion Pharmaceuticals Ltd. Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
JP2005533813A (ja) * 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ATE427933T1 (de) 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
BRPI0411594A (pt) * 2003-06-17 2006-08-29 Pfizer derivados de n-pirrolidin-3-il-amida como inibidores de re-absorção de serotonina e noradrenalina

Also Published As

Publication number Publication date
DE602004014372D1 (de) 2008-07-24
IL172063A0 (en) 2009-02-11
HRP20050993A2 (en) 2006-03-31
KR100803796B1 (ko) 2008-02-14
AU2004247487B2 (en) 2010-05-20
MXPA05013960A (es) 2006-02-24
AR044715A1 (es) 2005-09-21
MA27885A1 (fr) 2006-05-02
NL1026438C2 (nl) 2005-09-20
NL1026438A1 (nl) 2004-12-20
ECSP056232A (es) 2006-04-19
ES2305776T3 (es) 2008-11-01
TW200505852A (en) 2005-02-16
AU2004247487A1 (en) 2004-12-23
KR20060036927A (ko) 2006-05-02
JP4137159B2 (ja) 2008-08-20
PT1638933E (pt) 2008-07-22
WO2004110995A1 (en) 2004-12-23
NZ544046A (en) 2009-08-28
EA200501730A1 (ru) 2006-08-25
DK1638933T3 (da) 2008-07-28
EA009881B1 (ru) 2008-04-28
PE20050631A1 (es) 2005-09-14
PA8605301A1 (es) 2005-02-04
HRP20080339T3 (en) 2008-08-31
ATE398107T1 (de) 2008-07-15
US7378436B2 (en) 2008-05-27
AP2005003467A0 (en) 2006-12-31
EP1638933B1 (en) 2008-06-11
WO2004110995A8 (en) 2005-04-21
EP1638933A1 (en) 2006-03-29
IS8136A (is) 2005-11-21
CA2530159A1 (en) 2004-12-23
US20050137229A1 (en) 2005-06-23
CA2530159C (en) 2010-02-02
SI1638933T1 (sl) 2008-10-31
UY28360A1 (es) 2005-01-31
US20080306123A1 (en) 2008-12-11
CY1110434T1 (el) 2015-04-29
PL1638933T3 (pl) 2008-10-31
JP2006527758A (ja) 2006-12-07

Similar Documents

Publication Publication Date Title
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
ECSP056232A (es) Nuevos compuestos
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
UA101328C2 (uk) Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met
BRPI0812877A2 (pt) " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ".
SG179437A1 (en) Pyrimidine hydrazide compounds as pgds inhibitors
ATE459622T1 (de) Tropanverbindungen
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
BRPI0507462A (pt) compostos de quinolina substituìdos
WO2010129500A3 (en) Nematocidal sulfonamides
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
BRPI0506988A (pt) carboxamidas como inibidores de fator xa
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
MX2010003849A (es) Antagonistas de cgrp.
BRPI0510412A (pt) compostos orgánicos
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
BRPI0811204A8 (pt) Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BRPI0513891A (pt) derivados de propenil piperazina substituìdos como novos inibidores de histona deacetilase
WO2011087837A3 (en) Fungicidal 2-(bicyclic aryloxy)carboxamides
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
WO2009007536A3 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
WO2008022060A3 (en) Imidazo-pyridine derivatives for modulating protein kinase activity

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.